SCHOTT, a global leader in specialty glass, has expanded its manufacturing operations in Jambusar, Gujarat, with the launch of locally produced syringe and cartridge glass tubing. This development strengthens India’s capabilities in pharmaceutical packaging and makes SCHOTT the largest producer of syringe and cartridge glass tubing in Asia.
The new production line is based on direct technology transfer from SCHOTT’s facilities in Germany and is designed to meet rising demand for advanced drug delivery systems, particularly in the biologics segment. One key application includes GLP-1 receptor agonists like semaglutide, used in treatments for type 2 diabetes and weight management—an area expected to grow at a compound annual rate of 33%.
With this addition, SCHOTT now offers a complete local supply chain for glass primary packaging in India, including vials, ampoules, prefillable syringes, and cartridges. “This marks an important step in strengthening India’s pharmaceutical infrastructure,” said Sundeep Prabhu, Senior Vice President of Sales & Marketing at SCHOTT Glass India. “As the first company to manufacture this category of glass tubing locally, we’re enhancing our production capabilities while contributing to India’s healthcare resilience. Our investment is aligned with the ‘Make in India’ vision and supports the country’s long-term economic and industrial growth.”
SCHOTT’s FIOLAX® Type I borosilicate glass is used worldwide for parenteral packaging due to its high chemical resistance, dimensional accuracy, and consistent quality. The newly introduced syringe and cartridge tubing benefit from ultra-precise inner diameter tolerances—critical for ensuring drug stability, smooth plunger movement, and accurate dosing.
“Our focus isn’t only on increasing capacity—it’s on building long-term reliability for critical drug delivery components,” said Pawan Kumar Shukla, President & Managing Director of SCHOTT Glass India. “By producing FIOLAX® syringe and cartridge tubing locally, and using technologies like our perfeXion® quality system that analyzes 100,000 data points per minute, we aim to deliver top-tier quality with zero-defect standards.”
India was selected for this expansion due to its rapidly growing pharmaceutical sector, availability of skilled talent, and supportive policy environment. This move also enables knowledge transfer in advanced glass manufacturing and supports supply chain stability for the wider region.
SCHOTT, founded in 1884 and headquartered in Mainz, Germany, is a global technology group operating in over 30 countries with more than 17,000 employees. It serves industries including healthcare, electronics, and aerospace, and is owned by the Carl Zeiss Foundation. The company reported €2.8 billion in sales in fiscal 2024 and is committed to climate-neutral production as part of its sustainability goals.
SCHOTT Glass India Pvt Ltd, a wholly owned subsidiary established in 1998, operates the company’s second-largest pharmaceutical tubing plant in Jambusar. This site plays a key role in supplying high-quality glass tubing for injectable medicines across India and broader Asian markets.
